Xiangyu Medical (688626) Limit-Up Analysis and Future Trend Prediction

The direct trigger for Xiangyu Medical’s limit-up is

[4][5][6]. This news greatly boosted the market’s industrialization expectations for the brain-computer interface industry and drove the entire sector to boom. The company itself has clear layout support in the brain-computer interface field: it started R&D in 2015, owns core intellectual property rights [7], has obtained registration certificates for two products [9], plans to release about 30 brain-computer interface products in January 2026, and aims to exceed 100 million yuan in revenue for this sector in 2026 [10], which is not purely concept speculation.

On the day, the company sealed the board with a 20% increase, closing at 72.6 yuan per share,

[1][2][3]. The brain-computer interface sector performed strongly overall, with a half-day increase of 12.56%, and more than 20 concept stocks hit the limit-up [11]. Although specific trading volume data was not obtained, as a leading stock in the sector, the trading volume is expected to be significantly higher than the recent average, indicating high enthusiasm for capital participation [4][5].

The brain-computer interface sector became the hottest sector on the first trading day of A-shares in 2026, with extremely high market sentiment [12]. At the policy level, China has included brain science and brain-like research in major science and technology projects, and many places have introduced special support policies [13]; on the medical side, there is an urgent demand for rehabilitation of diseases such as paralysis and speech disorders, which further amplified the sector’s popularity. Investors are full of expectations for the application prospects of brain-computer interfaces in rehabilitation medical care, and companies with substantial technical reserves and commercialization plans have become the focus of capital pursuit [14].

1. Sector Linkage Effect
   : Neuralink’s mass production news not only affected U.S. stocks but also quickly spread to the A-share brain-computer interface sector, showing that the linkage impact of global technology hotspots on domestic concept stocks has increased.
2. Core Competitiveness Highlighted
   : Against the background of the collective boom of the sector, companies with actual technology implementation and commercialization plans (such as Xiangyu Medical) are more likely to be favored by capital, forming a differentiation from purely concept speculation companies.
3. Policy and Demand Resonance
   : The domestic brain-computer interface industry not only benefits from national policy support but also has a clear medical demand foundation. Its long-term development potential is worthy of attention, but in the short term, we need to be vigilant about fluctuations caused by overheated sentiment.

1. Valuation Bubble Risk
   : Currently, the price-to-earnings ratio is 198.08 times, far higher than the industry average, with relatively large short-term valuation pressure [1][2][3].
2. Industrial Uncertainty
   : The brain-computer interface industry is still in the early stage of industrialization, and there are great uncertainties in the pace of technology implementation and commercialization capabilities [15].
3. Increased Competition Risk
   : As more companies enter this field, market competition will become increasingly fierce in the future [17].
4. Sentiment Callback Risk
   : If the sector sentiment cools down or the company’s subsequent progress is less than expected, it may face callback pressure [16].

1. Technology Implementation Opportunity
   : The company has obtained product registration certificates and plans to release new products in batches, and is expected to be the first to share the growth dividends of the brain-computer interface rehabilitation medical market [10].
2. Policy Support Opportunity
   : Domestic brain-computer interface industry policies are gradually improving, providing a good environment for the company’s development [13].

Xiangyu Medical’s limit-up was mainly affected by the boom of the brain-computer interface sector catalyzed by Neuralink’s mass production news. The company’s own technical reserves and commercialization plans provided substantial support for the limit-up. Currently, market sentiment is extremely high, but the valuation is relatively high, and the industry is still in the early stage of development with great uncertainties. Investors need to pay attention to the sustainability of the limit-up board, the support level around 70 yuan, and subsequent changes in trading volume, and make cautious decisions based on the company’s long-term technical progress and industry development rhythm.